While several C. difficile adhesins have been characterized, protein purification can be time-consuming and expensive. To
develop a non-toxic and relatively inexpensive alternative to antibiotic therapy, we considered ntCDMF as a vaccine candidate. Nontoxigenic C. difficile was used to avoid the risk of contamination of toxins in the membrane fraction.